Duncan I Jodrell
Overview
Explore the profile of Duncan I Jodrell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
4385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi M, So T, Chamberlain-Evans V, Hughes R, Yam-Puc J, Kania K, et al.
Sci Immunol
. 2024 May;
9(95):eade2094.
PMID: 38787961
Immunotherapy advances have been hindered by difficulties in tracking the behaviors of lymphocytes after antigen signaling. Here, we assessed the behavior of T cells active within tumors through the development...
2.
Graziano V, Dannhorn A, Hulme H, Williamson K, Buckley H, Karim S, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37553182
Background: The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. It has been suggested that the adenosine pathway contributes to the ability of PDAC to evade the...
3.
Bistrovic Popov A, Melle F, Linnane E, Gonzalez-Lopez C, Ahmed I, Parshad B, et al.
Nanoscale
. 2022 Apr;
14(17):6656-6669.
PMID: 35438701
Nanocarriers have emerged as one of the most promising approaches for drug delivery. Although several nanomaterials have been approved for clinical use, the translation from lab to clinic remains challenging....
4.
Petruzzelli M, Ferrer M, Schuijs M, Kleeman S, Mourikis N, Hall Z, et al.
Cancers (Basel)
. 2022 Feb;
14(4.
PMID: 35205709
An elevated neutrophil-lymphocyte ratio negatively predicts the outcome of patients with cancer and is associated with cachexia, the terminal wasting syndrome. Here, using murine model systems of colorectal and pancreatic...
5.
Strittmatter N, Richards F, Race A, Ling S, Sutton D, Nilsson A, et al.
Anal Chem
. 2022 Jan;
94(3):1795-1803.
PMID: 35005896
Gemcitabine (dFdC) is a common treatment for pancreatic cancer; however, it is thought that treatment may fail because tumor stroma prevents drug distribution to tumor cells. Gemcitabine is a pro-drug...
6.
Li D, Schaub N, Guerin T, Bapiro T, Richards F, Chen V, et al.
Mol Cancer Ther
. 2021 Aug;
20(10):1926-1940.
PMID: 34376576
The desmoplastic stroma of pancreatic cancers forms a physical barrier that impedes intratumoral drug delivery. Attempts to modulate the desmoplastic stroma to increase delivery of administered chemotherapy have not shown...
7.
Johnson T, Minteer C, Kottmann D, Dunlop C, Fernandez S, Carnevalli L, et al.
EBioMedicine
. 2021 May;
68:103396.
PMID: 34049239
Background: Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell...
8.
Maki-Petaja K, McGeoch A, Yang L, Hubsch A, Mceniery C, Meyer P, et al.
Hypertension
. 2021 Mar;
77(5):1591-1599.
PMID: 33775123
[Figure: see text].
9.
Biasci D, Smoragiewicz M, Connell C, Wang Z, Gao Y, Thaventhiran J, et al.
Proc Natl Acad Sci U S A
. 2020 Oct;
117(46):28960-28970.
PMID: 33127761
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer responses in murine and human pancreatic cancer. Here...
10.
Dunlop C, Wallez Y, Johnson T, Fernandez S, Durant S, Cadogan E, et al.
Br J Cancer
. 2020 Aug;
123(9):1424-1436.
PMID: 32741974
Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738,...